India, July 19 -- The U.S. Food and Drug Administration announced that it has placed Sarepta Therapeutics' (SRPT) investigational gene therapy trials for limb-girdle muscular dystrophy on clinical hold following three patient deaths potentially linked to the therapies. The decision stems from new safety concerns indicating that participants may face an unreasonable and significant risk of illness or injury. The FDA also revoked Sarepta's platform technology designation.
The FDA requested that Sarepta voluntarily halt all shipments of ELEVIDYS, but the company declined to comply.
SRPT closed Friday regular trading at $14.07 down $7.89 or 35.94%. In after hours trading, the stock further dopped $0.70 or 5.01%.
In a separate press release, ...